Initiating, facilitating, expediting, auditing, analyzing, evaluating, verifying, deconstructing, and managing communications, studies, information, and documents in the field of pharmaceuticals, so as to inform pharma companies and their investors of the realistic potential for particular pharma products to reach the market and realize a profit. This will involve cutting through technical jargon to give pharma execs and investors a plain language assessment of the product under study so as to guide investment choices and direct funds to the most promising products, where necessary switching to surrogate products to replace those which cannot withstand rigorous technical scrutiny with our world renowned experts with a combined experience of over 30 years each. The aim is enable informed decision making and avoid reliance on claims which ultimately prove to be specious and lead to litigation.